AR077427A1 - Otamixaban para el tratamiento de pacientes con alteracion renal y de edad avanzada con infarto de miocardio sin elevacion del st - Google Patents
Otamixaban para el tratamiento de pacientes con alteracion renal y de edad avanzada con infarto de miocardio sin elevacion del stInfo
- Publication number
- AR077427A1 AR077427A1 ARP100102707A ARP100102707A AR077427A1 AR 077427 A1 AR077427 A1 AR 077427A1 AR P100102707 A ARP100102707 A AR P100102707A AR P100102707 A ARP100102707 A AR P100102707A AR 077427 A1 AR077427 A1 AR 077427A1
- Authority
- AR
- Argentina
- Prior art keywords
- elevation
- treatment
- miocardio
- infarto
- otamixaban
- Prior art date
Links
- PFGVNLZDWRZPJW-OPAMFIHVSA-N otamixaban Chemical compound C([C@@H](C(=O)OC)[C@@H](C)NC(=O)C=1C=CC(=CC=1)C=1C=C[N+]([O-])=CC=1)C1=CC=CC(C(N)=N)=C1 PFGVNLZDWRZPJW-OPAMFIHVSA-N 0.000 title abstract 2
- 229950009478 otamixaban Drugs 0.000 title 1
- 208000011728 renal alteration Diseases 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- -1 3-carbamimidoyl-benzyl Chemical group 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 150000004702 methyl esters Chemical class 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/12—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with only hydrogen atoms attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Uso de éster metílico del ácido (2R,3R)-2-(3-carbamimidoil-bencil)-3-[4-(1-oxi-piridin-4-il)benzoilamino]-butírico o una sal farmacéuticamente aceptable del mismo, para la preparacion de un medicamento para su uso en el infarto de miocardio sin elevacion del ST, comprendiendo dicho tratamiento administrar una cantidad terapéuticamente eficaz de éster metílico del ácido (2R,3R)-2-(3-carbamimidoil-bencil)-3-[4-(1-oxi-piridin-4-il)benzoilamino]-butírico o una sal farmacéuticamente aceptable del mismo a un paciente humano, de edad avanzada y/o que muestra insuficiencia renal y/o tiene un bajo peso corporal.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09290601 | 2009-07-29 | ||
| EP10305192 | 2010-02-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR077427A1 true AR077427A1 (es) | 2011-08-24 |
Family
ID=42542846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100102707A AR077427A1 (es) | 2009-07-29 | 2010-07-27 | Otamixaban para el tratamiento de pacientes con alteracion renal y de edad avanzada con infarto de miocardio sin elevacion del st |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9492437B2 (es) |
| EP (1) | EP2459193A1 (es) |
| JP (1) | JP2013500298A (es) |
| KR (1) | KR20120038982A (es) |
| CN (1) | CN102470128A (es) |
| AR (1) | AR077427A1 (es) |
| AU (1) | AU2010277725B2 (es) |
| BR (1) | BR112012001900A2 (es) |
| CA (1) | CA2766533A1 (es) |
| CL (1) | CL2012000196A1 (es) |
| CO (1) | CO6491041A2 (es) |
| CR (1) | CR20110674A (es) |
| DO (1) | DOP2012000012A (es) |
| EC (1) | ECSP12011627A (es) |
| IL (1) | IL217612A (es) |
| MA (1) | MA33455B1 (es) |
| MX (1) | MX2012000457A (es) |
| NI (1) | NI201200008A (es) |
| NZ (1) | NZ597957A (es) |
| PE (1) | PE20121401A1 (es) |
| RU (1) | RU2542455C2 (es) |
| SG (1) | SG177772A1 (es) |
| TW (1) | TWI463982B (es) |
| UY (1) | UY32807A (es) |
| WO (1) | WO2011012527A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2691371T1 (sl) * | 2011-03-29 | 2015-07-31 | Sanofi | Sol benzojske kisline otamiksabana |
| TWI551289B (zh) * | 2011-03-29 | 2016-10-01 | 賽諾菲公司 | 具有改良之安定性之奧米沙班調配物 |
| WO2012130819A1 (en) | 2011-03-29 | 2012-10-04 | Sanofi | Otamixaban formulations with improved stability |
| EA201590473A1 (ru) | 2012-08-31 | 2015-06-30 | Санофи | Отамиксабан для применения в лечении острого коронарного синдрома без подъема st у пациентов, которым планируется проведение аортокоронарного шунтирования |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2241904C (en) | 1996-01-02 | 2004-12-21 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides |
| RU2225617C1 (ru) * | 2002-12-16 | 2004-03-10 | Научно-исследовательский институт кардиологии Томского научного центра СО РАМН | Способ определения дифференцированного назначения гепаринов больным с острым коронарным синдромом без подъема сегмента st |
-
2010
- 2010-07-22 SG SG2012006110A patent/SG177772A1/en unknown
- 2010-07-22 CA CA2766533A patent/CA2766533A1/en not_active Abandoned
- 2010-07-22 PE PE2012000036A patent/PE20121401A1/es not_active Application Discontinuation
- 2010-07-22 MA MA34566A patent/MA33455B1/fr unknown
- 2010-07-22 CN CN2010800323309A patent/CN102470128A/zh active Pending
- 2010-07-22 US US13/387,639 patent/US9492437B2/en not_active Expired - Fee Related
- 2010-07-22 WO PCT/EP2010/060615 patent/WO2011012527A1/en not_active Ceased
- 2010-07-22 BR BR112012001900A patent/BR112012001900A2/pt not_active IP Right Cessation
- 2010-07-22 RU RU2012107483/15A patent/RU2542455C2/ru not_active IP Right Cessation
- 2010-07-22 JP JP2012522112A patent/JP2013500298A/ja active Pending
- 2010-07-22 EP EP10735284A patent/EP2459193A1/en not_active Withdrawn
- 2010-07-22 MX MX2012000457A patent/MX2012000457A/es active IP Right Grant
- 2010-07-22 AU AU2010277725A patent/AU2010277725B2/en not_active Ceased
- 2010-07-22 KR KR1020127002078A patent/KR20120038982A/ko not_active Ceased
- 2010-07-22 NZ NZ597957A patent/NZ597957A/en not_active IP Right Cessation
- 2010-07-27 UY UY0001032807A patent/UY32807A/es not_active Application Discontinuation
- 2010-07-27 AR ARP100102707A patent/AR077427A1/es unknown
- 2010-07-27 TW TW099124612A patent/TWI463982B/zh not_active IP Right Cessation
-
2011
- 2011-12-15 CR CR20110674A patent/CR20110674A/es unknown
-
2012
- 2012-01-12 NI NI201200008A patent/NI201200008A/es unknown
- 2012-01-16 CO CO12005490A patent/CO6491041A2/es not_active Application Discontinuation
- 2012-01-18 IL IL217612A patent/IL217612A/en not_active IP Right Cessation
- 2012-01-19 DO DO2012000012A patent/DOP2012000012A/es unknown
- 2012-01-24 CL CL2012000196A patent/CL2012000196A1/es unknown
- 2012-01-26 EC EC2012011627A patent/ECSP12011627A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9492437B2 (en) | 2016-11-15 |
| BR112012001900A2 (pt) | 2016-03-15 |
| KR20120038982A (ko) | 2012-04-24 |
| CN102470128A (zh) | 2012-05-23 |
| AU2010277725A1 (en) | 2012-02-16 |
| MX2012000457A (es) | 2012-01-27 |
| UY32807A (es) | 2011-02-28 |
| MA33455B1 (fr) | 2012-07-03 |
| TW201119655A (en) | 2011-06-16 |
| DOP2012000012A (es) | 2012-02-15 |
| US20120238605A1 (en) | 2012-09-20 |
| PE20121401A1 (es) | 2012-10-25 |
| NI201200008A (es) | 2012-05-29 |
| CL2012000196A1 (es) | 2012-10-05 |
| EP2459193A1 (en) | 2012-06-06 |
| CA2766533A1 (en) | 2011-02-03 |
| NZ597957A (en) | 2014-05-30 |
| IL217612A (en) | 2014-08-31 |
| RU2542455C2 (ru) | 2015-02-20 |
| JP2013500298A (ja) | 2013-01-07 |
| WO2011012527A1 (en) | 2011-02-03 |
| ECSP12011627A (es) | 2012-02-29 |
| SG177772A1 (en) | 2012-03-29 |
| TWI463982B (zh) | 2014-12-11 |
| CR20110674A (es) | 2012-04-17 |
| CO6491041A2 (es) | 2012-07-31 |
| RU2012107483A (ru) | 2013-09-10 |
| AU2010277725B2 (en) | 2016-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015025464A2 (pt) | coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico | |
| EA201491285A1 (ru) | Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| CL2016002132A1 (es) | Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo. | |
| CL2017000830A1 (es) | Formulación estable que comprende un azúcar no reductora, un anticuerpo anti-s4b7 y al menos un aminoácido libre; un método para preparar dicha formulación; uso de dicha formulación para tratar una enfermedad inflamatoria del intestino. | |
| PE20150161A1 (es) | Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| CL2011002858A1 (es) | Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor. | |
| NZ702801A (en) | Treatment of sanfilippo syndrome type b | |
| EA201491479A1 (ru) | Производные лупановых тритерпеноидов и их фармацевтическое применение | |
| ECSP15008695A (es) | Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa | |
| NZ606993A (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
| MX2018005729A (es) | Composiciones terapeuticas para tratamiento del virus de inmunodeficiencia humana. | |
| EA201490378A1 (ru) | ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β | |
| PE20141012A1 (es) | Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparacion | |
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| ECSP12011627A (es) | Otamixaban para el tratamiento de pacientes con alteración renal y de edad avanzada con infarto de miocardio sin elevación del st | |
| ECSP10010553A (es) | Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre | |
| UY33453A (es) | Método para el tratamiento de la hipertensión pulmonar mediante el uso de ranozalina | |
| EA201270747A1 (ru) | Композиции и способы для профилактики и лечения ран | |
| UA100883C2 (ru) | Применение дронедарона для получения лекарственного средства для лечения пациентов с аритмией и с повышенным уровнем креатинина в результате введения дронедарона | |
| AR094063A1 (es) | Uso de aclidinio, composicion farmaceutica y metodo para mejorar la actividad fisica en pacientes respiratorios | |
| EA201590732A1 (ru) | Диспергируемая таблетка | |
| TN2011000672A1 (en) | Otamixaban for treatment of elderly and renal impaired non st-elevation myocardial patients | |
| AR061046A1 (es) | Mirtazapina para el tratamiento del dolor neuropatico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |